Abstract
In this talk, I will describe why and how peptide based therapies are increasingly gaining popularity and the significant role that has been played in the process by an interdisciplinary effort combining design, MD simulations and experiments. Peptides constitute a "manageable" size between small molecules and antibodies. The ability to constrain them against degradation and access both extracellular and intracellular targets makes them quite versatile. More recent innovations in formulations are rapidly overcoming concerns of delivery. Finally the issues of tackling the emergence of resistance see some promise in peptides and will be discussed.

Biography
Chandra Verma graduated from IIT Kanpur, India and then obtained a PhD at the Univ of York, UK. He worked in York until the end of 2003 when he moved to run a research group at the Bioinformatics Instt (A*STAR), Singapore. His main interests are in applications of modelling and simulations to a variety of biological problems and the group has developed several small molecules and peptides as antimicrobials, anti-inflammatories and in oncology, working in close collaboration with experimentalists, clinicians and pharma companies.

Related recent references: